AEMD - エスロン・メディカル (Aethlon Medical Inc.) エスロン・メディカル



symbol AEMD
会社名 Aethlon Medical Inc (エスロン・メディカル)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 Aethlon Medical Inc. is a medical device company focused on creating devices for cancer infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon which represents its therapeutic business activities and ESI which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications the Hemopurifier targets the removal of circulating exosomes which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary Exosome Sciences Inc. (Exosome) the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.   エスロン・メディカルは米国の医療機器メ―カ―。がんや感染症疾患治療用ろ過装置の開発、製造に従事する。同社の「エスロン・キ―モピュ―リファイア」はHIVやC型肝炎ウイルスなどのウイルス性病原体治療用血液浄化フィルタ―で、患者の血液や腹水からエキソソ―ムを除去することが可能。また、乳がん用や敗血症用フィルタ―も扱う。本社はカリフォルニア州。   Aethlon Medical Inc is a medical technology company. It operates through two segments namely Aethlon for therapeutic applications and ESI for diagnostic applications.
本社所在地 9635 Granite Ridge Drive Suite 100 San Diego CA 92123 USA
代表者氏名 Rodney S. Kenley ロドニー・S・ケンリー
代表者役職名 President Director 社長
電話番号 +1 858-459-7800
設立年月日 33329
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 6人
EBITDA EBITDA(百万ドル) -4.73369
終値(lastsale) 1.07
時価総額(marketcap) 19044125.36
時価総額 時価総額(百万ドル) 19.75606
売上高 売上高(百万ドル) 0.29925
企業価値(EV) 企業価値(EV)(百万ドル) 14.50460
当期純利益 当期純利益(百万ドル) -4.98401
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Aethlon Medical Inc. revenues increased from $0K to $150K. Net loss decreased 38% to $1.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Loss on debt extinguishment decrease from $377K (expense) to $0K Amortization of Note Discounts decrease of 80% to $30K (expense).



   Aethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE Studies  2019-05-13 PR Newswire
PHOENIX , May 13, 2019 /PRNewswire/ -- Aethlon Medical Inc. (Nasdaq: AEMD) and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will e…

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 エスロン・メディカル AEMD Aethlon Medical Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)